Abstract
Objective
To illustrate the effectiveness of hysteroscopic endometrial resection in conservative treatment of early endometrial cancer/atypical hyperplasia in women of reproductive age.
Methods
Review of outcomes of women of reproductive age who underwent fertility sparing treatment (hysteroscopic superficial endometrectomy followed by progestin therapy) in early endometrial cancer.
Results
Eight women with Stage I endometrial cancer and three with atypical endometrial hyperplasia underwent hysteroscopic superficial endometrial resection, followed by 1-year treatment with oral megestrol acetate. One patient had a synchronous endometrioid ovarian carcinoma. One patient with Grade 2 carcinoma opted for conservative treatment and had hysterectomy 3 months later for persisting disease. Ten patients showed no evidence of residual disease during a 12-month follow-up period with regular hysteroscopy. Five patients had seven pregnancies without assisted reproductive technology. One patient got pregnant after one attempt of in-vitro fertilization and oocyte donation. Pregnancy rate was 54.5%; two patients had two successful pregnancies and deliveries. Average time to pregnancy was 16 months from the end of treatment. All babies were delivered vaginally.
Conclusion
Total superficial endometrial resection followed by progestin can be considered in patients with early endometrial cancer/atypical hyperplasia who still want to conceive. It does not seem to impair fertility nor pregnancy outcomes in women of reproductive age.
Similar content being viewed by others
References
Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29
SEER (2011) Cancer statistics review, 1975–2008. National Cancer Institute. http://seer.cancer.gov/csr/1975_2008/. Accessed 12 Sept 2020
Creasman WT, Odicino F, Maisonneuve P et al (2001) Carcinoma of the corpus uteri. J Epidemiol Biostat 6:47–86
Gitsch G, Hanzal E, Jensen D, Hacker NF (1995) Endometrial cancer in premenopausal women 45 years and younger. Obstet Gynecol 85:504–508
Adenocarcinoma of the uterus (2002). In: Di Saia PJ, Creasman WT (eds) Clinical gynecologic oncology. Elsevier, pp 289–350 (St. Louis, MO7 Mosby Inc)
Committee on Gynecologic Practice, Society of Gynecologic Oncology (2015) The American college of obstetricians and gynecologists committee opinion no. 631: endometrial intraepithelial neoplasia. Obstet Gynecol. 125(5):1272–1278
DiSaia PJ, Creasman WT, Boronow RC, Blessing JA (1985) Risk factors and recurrent patterns in stage I endometrial cancer. Am J Obstet Gynecol 151(8):1009–1015
Creasman WT, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz AP et al (2003) Carcinoma of the corpus uteri. Int J Gynaecol Obstet 83(Suppl 1):79–118
Kim YB, Holschneider CH, Ghosh K et al (1997) Progestin alone as primary treatment of endometrial carcinoma in premenopausal women: report of seven cases and review of the literature. Cancer 79:320–327
Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C (2004) Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 95(1):133–138
Kalogera E, Dowdy SC, Bakkum-Gamez JN (2014) Preserving fertility in young patients with endometrial cancer: current perspectives. Int J Womens Health 6:691–701
Laurelli G, Di Vagno G, Scaffa C, Losito S, Del Giudice M, Greggi S (2011) Conservative treatment of early endometrial cancer: preliminary results of a pilot study. Gynecol Oncol 120(1):43–46
Mazzon I, Corrado G, Masciullo V, Morricone D, Ferrandina G, Scambia G (2010) Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. Fertil Steril 93(4):1286–1289
Amant F, Mirza MR, Koskas M, Creutzberg CL (2018) Cancer of the corpus uteri. Int J Gynaecol Obstet 143(Suppl 2):37–50
Atallah D, Safi J, El Kassis N, Rouzier R, Chahine G (2013) Simultaneous early ovarian and endometrial cancer treated conservatively with spontaneous pregnancy. J Ovarian Res 6:59
Kempson RL, Pokorny GE (1968) Adenocarcinoma of the endometrium in women aged forty and younger. Cancer 21(4):650–662
O’Neill RT (1970) Pregnancy following hormonal therapy for adenocarcinoma of the endometrium. Am J Obstet Gynecol 108(2):318–321
Koskas M, Uzan J, Luton D, Rouzier R, Daraï E (2014) Prognostic factors of oncologic and reproductive outcomes in fertility sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertil Steril 101(3):785–794
Rodolakis A, Biliatis I, Morice P, Reed N, Mangler M, Kesic V et al (2015) European Society of Gynecological Oncology Task Force for Fertility Preservation: clinical recommendations for fertility-sparing management in young endometrial cancer patients. Int J Gynecol Cancer 25(7):1258–1265
Gunderson CC, Fader AN, Carson KA, Bristow RE (2012) Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol 125(2):477–482
Gallos ID, Yap J, Raikhowa M, Luesley DM, Coomarasamy A, Gupta JK (2012) Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia. Am J Obstet Gynecol 207(4):266.e1-266.e12
Shan BE, Ren YL, Sun JM, Tu XY, Jiang ZX, Ju XZ et al (2013) A prospective study of fertility-sparing treatment with megestrol acetate following hysteroscopic curettage for well-differentiated endometrioid carcinoma and atypical hyperplasia in young women. Arch Gynecol Obstet 288(5):1115–1123
De Marzi P, Bergamini A, Luchini S, Petrone M, Taccagni GL, Mangili G et al (2015) Hysteroscopic resection in fertility-sparing surgery for atypical hyperplasia and endometrial cancer: safety and efficacy. J Minim Invasive Gynecol 22(7):1178–1182
Alonso S, Castellanos T, Lapuente F, Chiva L (2015) Hysteroscopic surgery for conservative management in endometrial cancer: a review of the literature. Ecancermedicalscience 9:505
Gonthier C, Luton D, Koskas M (2015) Extended endometrial ablation risks in the fertility sparing management of adenocarcinoma and atypical hyperplasia of the endometrium. Gynecol Obstet Fertil 43(3):185–186
Cook JR, Seman EI (2003) Pregnancy following endometrial ablation: case history and literature review. Obstet Gynecol Surv 58(8):551–556
Falcone F, Laurelli G, Losito S et al (2017) Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer. J Gynecol Oncol 28(1):e2
Fan Z, Li H, Hu R, Liu Y, Liu X, Gu L (2018) Fertility-preserving treatment in young women with grade 1 presumed stage IA endometrial adenocarcinoma: a meta-analysis. Int J Gynecol Cancer 28(2):385–393
Gonthier C, Trefoux-Bourdet A, Koskas M (2017) Impact of conservative managements in young women with grade 2 or 3 endometrial adenocarcinoma confined to the endometrium. Int J Gynecol Cancer 27(3):493–499
Chen M, Jin Y, Li Y, Bi Y, Shan Y, Pan L (2016) Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer. Int J Gynaecol Obstet 132(1):34–38
AlHilli MM, Dowdy SC, Weaver AL, St Sauver JL, Keeney GL, Mariani A et al (2012) Incidence and factors with synchronous ovarian and endometrial cancer: a population based case–control study. Gynecol Oncol 125(1):109–113
Baker WD, Pierce SR, Mills AM, Gehrig PA, Duska LR (2017) Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women. Gynecol Oncol 146(1):34–38
Gonthier C, Trefoux-Bourdet A, Luton D, Koskas M (2017) Fertility-sparing management of endometrial cancer and atypical hyperplasia. Gynecol Obstet Fertil Senol 45(2):112–118
Fujimoto A, Ichinose M, Harada M, Hirata T, Osuga Y, Fujii T (2014) The outcome of infertility treatment in patients undergoing assisted reproductive technology after conservative therapy for endometrial cancer. J Assist Reprod Genet 31(9):1189–1194
Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z (2005) Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 23(19):4347–4353
Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, Wallace WH, Wang ET, Loren AW (2018) Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 36(19):1994–2001
Concin N, Matias-Guiu X, Vergote I et al (2020) ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. https://doi.org/10.1136/ijgc-2020-002230 (Published Online First)
Acknowledgements
The authors are thankful to all patients who participated in the study.
Funding
None.
Author information
Authors and Affiliations
Contributions
DA: study conception, data collection and analysis, patients’ treatment, surgery and follow-up, and drafting of the paper. NK: data collection and analysis, patients’ treatment, drafting of the paper. JS: patients’ treatment, drafting of the paper. HEH: patients’ treatment, drafting of the paper. GC: patients’ treatment, drafting of the paper. MM: study conception, data collection and analysis, patients’ treatment, drafting of the paper. All authors reviewed and approved the final version of the paper.
Corresponding author
Ethics declarations
Conflict of interest
The author(s) declare that they have no conflict of interest
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Atallah, D., El Kassis, N., Safi, J. et al. The use of hysteroscopic endometrectomy in the conservative treatment of early endometrial cancer and atypical hyperplasia in fertile women. Arch Gynecol Obstet 304, 1299–1305 (2021). https://doi.org/10.1007/s00404-021-06048-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-021-06048-0